CARTI To Serve As First Center In Us To Treat Patients Through Embrace Hydrogel Embolic System Global Randomized Multi-Center Clinical Trial
Pivotal study to evaluate the use of novel liquid embolic verses standard of care in treating malignant and benign hypervascular tumors CARTI today announced its participation in the Instylla, Inc. Embrace Hydrogel Embolic System (HES™) global randomized clinical trial for the treatment of hypervascular tumors. As demonstrated previously in the completed First-in-Human (FIH) study, Embrace … Continued